ALLIST Announces IND Approvals of AST1001, Its First In-house ADC, from China NMPA and the U.S. FDA

Allist Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC

Allist Pharmaceuticals In-Licenses Potential First-in-Class ADC to Expand New Therapeutic Areas

Major Announcement | Glecirasib Citrate Tablets Approved for Market Launch, Opening a New Chapter in KRASG12C-Mutated Advanced NSCLC Treatment

Allist Pharmaceuticals and Abbisko Therapeutics Jointly Announce the Initiation of a Phase 2 Clinical Study Evaluating oral PD-L1 small molecule ABSK043 in Combination with Furmonertinib Mesylate Tablets for the Treatment of Advanced Non-Small Cell Lung Cancer

Great New | Allist Annouces that FDA Grants Breakthrough Therapy Designation to Furmonertinib in First-Line Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Spotlight for Furmonertinib – NSCLC with EGFR Exon 20 Insertions Data Public at 2023 WCLC

Furmonertinib Received New Indication IND Approval by CDE – Comprehensive Cover, Global Synchronization

Fantastic News! Allist Pharmaceuticals Welcome Prestigious Scientists to Join Science Advisory Broad (SAB)

Allist Pharmaceuticals Annouced Today the Signing of a License Agreement with Abbisko Therapeutics for a New Generation of EGFR TKI, called ABK3376